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Abstract Gadolinium-based magnetic resonance imaging
(MRI) contrast agents (Gad-CA) were formerly considered
as alternatives to X-ray-employed iodinated media. Although
originally thought to be nonnephrotoxic and proven to be
nonhazardous in a healthy population, the Gad-CA safety
issue is progressively more controversial in the high-risk
group of end-stage renal disease (ESRD) patients. Recently,
Gad-CAs have not only been blamed for harmless side effects
such as dizziness or nausea but also for much more severe
complications such as acute renal failure, pancreatitis, or even
the development of so-called “nephrogenic systemic fibrosis”
in patients with renal failure, culminating in the prohibition of
gadodiamide (Omniscan) administration in ESRD patients
and, due to renal-organ immaturity, in newborns and infants
up to 1 year old. This editorial is written to give insights into
the molecular structure of Gad-CAs as well as into the
potential biochemical pathomechanisms underlying the afore-
mentioned severe clinical manifestations. Furthermore, a
review about the latest literature on Gad-CA nephrotoxicity
is provided. Potential risk factors are mentioned and strategies
to avoid deterioration of renal function are presented. Cases
with Gad-CA-associated adverse events should be adequately
documented and reported appropriately. MRI professionals
should collaborate closely with their colleagues from other
medical specialties to identify patients with adverse events.
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As nephrologists and colleagues working with magnetic
resonance imaging (MRI), we generally take for granted the
relative safety of gadolinium contrast agents (Gad-CA) in
terms of their nonadverse effects on our patients. On 7
February 2007, the medical community was informed that
gadodiamide (Omniscan) is now not only contraindicated in
patients with end-stage renal disease (ESRD), but also in
pre- or postoperative liver transplantation patients and, due
to their renal-organ immaturity, in newborns and infants up
to 1 year old. This change in policy was motivated by
recent reports of a possible link between the use of
gadodiamide and the development of so-called “nephro-
genic systemic fibrosis” (NSF) [1–4] in patients with renal
failure. This discovery came as quite a surprise to the
nephrology and radiology communities.
A glimpse into medical literature reveals approximately
200 cases of NSF, previously known as nephrogenic fibrosing
dermopathy (NFD) [1–6]. One pediatric case is published in
this issue [7]. NSF is characterized clinically by the
thickening, induration, and hardening of the skin in the
distal extremities, followed by the skin of the trunk but
usually omitting the face [8]. The diagnosis of NSF is
confirmed by skin biopsy. Characteristically, histopathologic
features such as thickened collagen bundles with surround-
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ing clefts, mucin deposition, and proliferation of fibroblasts
and elastic fibers are present, whereas signs of inflammation
are absent, which makes this disorder a distinct entity [2, 8].
Grobner [8] was the first to report that five of nine
gadodiamide-exposed hemodialysis patients developed NSF
within 2–4 weeks after contrast-dye exposure. A systemic
process is assumed in which circulating fibrocytes of bone
marrow origin are aberrantly recruited to various body sites,
including the skin, likely triggered or exacerbated by Gad-
induced endothelial damage [9]. Following this report,
Marckmann [10] also described 13 cases of NSF in patients
exposed to gadodiamide, progressing in more than 50% of
the cases to severe disability and even one patient death.
To date, there are eight Gad-based contrast media available
in Europe: gadobenate-dimeglumine (Multihance, Bracco
Diagnostics, Inc.), gadobutrol (Gadovist, Schering), gado-
diamide (Omniscan, GE Healthcare), gadofosveset (Vasovist,
Schering), gadopentetate-dimeglumine (Magnevist,
Schering), gadoteric acid (Dotarem, Guerbet), gadoteridol
(ProHance, Bracco Diagnostics Inc.), and gadoxetic acid
disodium (Primovist, Schering). In each product, the Gad ion
is chelated to various anion groups to form Gad salts [11].
The mechanism by which some Gad-CAs might trigger
NSF is still unresolved; however, several theories have
been proposed. Gad-CAs have different molecular struc-
tures that affect their biochemical properties. For example,
Omniscan and OptiMARK have a linear and uncharged
molecular configuration with excess chelate, which seems
to be more likely to release free gadolinium ions (Gd3+)
into the body, a process called transmetallation. Linear and
charged (e.g., Magnevist, MultiHance, Primovist, and
Vasovist) as well as cyclic and uncharged (e.g., Gadovist
and ProHance) Gad-CAs seem to be less likely to release
free Gd3+ into the body. Dotarem, for example, has a
molecular charge and a cyclical structure and is least known
for transmetallation. However, the exact mechanisms by
which free gadolinium ions can stimulate NSF is
unknown and therefore under investigation. Most of
the approximately 200 cases of NSF that were reviewed
so far in the literature have been associated with the
agents Gadodiamide (Omniscan) and Gadoversetamide
(OptiMARK, Mallinckrodt), which is not licensed for
use in the European Union (EU) but is available in the
USA. A small number of cases have been associated
with Gadopentetate Dimeglumine (Magnevist, Schering),
and to date, no cases of NSF have been associated with
other gadolinium-containing contrast agents.
These alarming reports give rise to a nagging question: Is
this just the tip of the iceberg? Have clinicians overlooked
other possible side effects of Gad? The widespread reliance on
Gad due to its nontoxicity probably needs to be reexamined.
These MRI contrast agents were originally introduced as
alternatives to iodinated media; iodine contrast dyes have
become the third most common cause of acute renal failure. In
patients with preexisting renal insufficiency, the incidence
was as high as 50% [6]. Although originally thought to be
nonnephrotoxic, Gad-based contrast media have recently
been implicated in various other critical incidents (apart from
NSF) in patients with ESRD. Again, a glance at the literature
reveals that colleagues have been studying Gad-contrast-
induced nephrotoxicity (CIN) since the early 1990s. CIN is
now defined by the European Society of Urogenital
Radiology (ESUR) [12] as an increase in serum creatinine
of more than 25%, or more than 0.5 mg/dl, occurring within
3 days after the intravascular administration of the contrast
medium in the absence of an alternative etiology. Interest-
ingly, the controversial results are mostly due to the differing
definitions of nephrotoxicity, patient’s collectives, renal
diseases, contrast agents, and contrast-agent concentrations
that have been employed and published. Unfortunately, there
are almost no published data on pediatric patients with renal
impairment.
As early as 1992, Haustein et al. [13] reported that Gad-
Diethylene triamine pentaacetic acid (DTPA) [0.1 mmol/kg
body weight (bw)] was harmless in a study of 21 patients
with chronic renal failure (creatinine clearance 34.5 ml/min).
Ten years later, Rieger et al. [5] described only one episode
of acute renal failure in 39 Gad-DTPA (0.35 mmol/kg bw)
angiographic imaging procedures for 29 patients (59% of
whom were diabetic) with renal insufficiency (mean serum
creatinine: 3.6 mg/dl). However, recent reports paint a
different picture. Erley et al. [14] recorded a significant
decline of renal function in 11 of 21 patients with severe
renal impairment (mean creatinine clearance 31 ml/min) after
gadobutrol (>0.5 mmol/kg) digital subtraction angiography.
In a larger study, Sam et al. [15] comprehensively
investigated 195 patients with chronic renal insufficiency
(creatinine clearance 38 ml/min) who were subjected to Gad
angiography (0.25 mmol/kg bw or more) and found that
acute renal failure developed in seven patients (3.5%).
Serum creatinine returned to baseline levels within 4–12 days
in five patients, but ESRD developed in two patients. In our
own collective of 50 patients with pre-ESRD or ESRD
referred for cardiovascular MRI dobutamine stress echo test,
and myocardial perfusion/viability, we observed a marked
systemic inflammatory response signalled by increased
inflammatory markers and fever up to 40°C and partial
hypereosinophilia in seven patients 24 h after Gad-DTPA
administration (0.3 mmol/kg bw). Acute renal failure was
experienced in two patients, one of whom did not recover.
Do we know what mechanisms lead to renal impairment
or systemic reaction after gad exposure? Unfortunately, due
to sparse data on the renal lesions associated with this
condition, very little is known about the mechanism of Gad
nephrotoxicity. The nephrotoxic effects of iodinated contrast
agents, which have been studied more intensely, are
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multifactorial, including a vasoconstrictive effect leading to
hypoxic or ischemic tubular cell injury and a direct
tubulotoxicity mediated by the generation of reactive
oxygen species [12]. As Gad-based and iodinated contrast
agents share the same pharmacodynamics [12, 15] and their
nephrotoxic effects are often clinically similar, they may
cause renal damage through the same mechanisms. The
mechanism of the severe inflammatory reaction is akin to a
massive allergic reaction, but the exact pathomechanism is
poorly understood. Initiation of dialysis may promptly
relieve the symptoms. Recently, Akgun [16] published a
renal biopsy study documenting a reversible acute tubular
cell injury in which patchy tubular cell necrosis and
degeneration along with mild interstitial edema and
inflammation were observed. The patient had been doubly
exposed to Gad in the forms of Gad-DTPA and gadopente-
tate. No significant glomerular or vascular changes were
observed.
Gad chelates are distributed in the extracellular space and
are eliminated almost exclusively by the kidney through
glomerular filtration. Renal failure impairs but maintains Gad
excretion without resorting to a nonrenal route. For example,
gadodiamide half-life is 1.3 h, 34.3 h, and 52.7 h in healthy
patients, patients with ESRD, and peritoneal dialysis patients,
respectively [17]. This extremely long half-life raises the
question of how to handle pediatric patients on peritoneal
dialysis (PD). Should they be hemodialyzed after Gad
exposure, or should Gad exposure be completely avoided
in PD patients? Further data are necessary to determine an
optimal form of treatment.
What other potential systemic Gad effects could be
responsible for the severe adverse events? Gadodiamide, for
example, leaves two to four times more Gad in the bone than
other contrast agents in patients with normal renal function
[10, 12]. Because of the longer half-life of Gad-based
contrast media in patients with ESRD, it could be speculated
that Gad liberation might be causing systemic effects.
Taken together, these issues confront us with the task of
correctly identifying and preparing our renal failure patients—
and especially pediatric patients—with ESRD who were
frequently treated with PD. At the same time, we must protect
them from an unjustified risk caused by the possibility of
adverse Gad-associated events. Raised serum creatinine levels
(particularly secondary to diabetic nephropathy), dehydration,
congestive heart failure, an age of over 70 years, and
concurrent administration of nephrotoxic drugs (nonsteroidal
anti-inflammatory drugs) are all considered potential risk
factors by the guidelines [12]. Consequently, patients
undergoing a diagnostic MRI scan with potential Gad
exposure should be well hydrated, low- or iso-osmolar
contrast media should be used, and nephrotoxic drugs should
have been stopped for at least 24 h. Alternatively, other
imaging techniques that do not require the administration of
Gad should be taken into consideration. All in all, the less
Gad, the better! In patients on continuous ambulatory PD
(CAPD) and severely reduced renal function, one should
avoid Gad doses exceeding 0.3 mmol/ kg bw [12].
The treatment of Gad-induced nephropathy begins with
recognizing the condition. Therefore, in high-risk patients, the
measurement of serum creatinine (a threshold of 1.5 mg/dl
may be the ideal level for Gad agents, as is common with
iodinated contrast agents) between the second and fourth day
post-MRI will identify the nonaffected patients. Additionally,
patients should not be reexposed to Gad before the kidney
function has returned to its previous state. If Gad contrast
media has to be administered again, the patients should at least
be adequately hydrated and nephrotoxic agents should be
stopped in due time.
Prompt hemodialysis within the first several hours after
MRI may be recommended for quick removal of the Gad
agent from the bloodstream. MRI professionals should
collaborate closely with their colleagues from other medical
specialties in the search to identify patients with Gad-
associated adverse events. Cases with a positive history of
exposure to Gad and adverse events should be adequately
documented and reported through the appropriate channels.
More data are required to clarify whether these complica-
tions are limited to one specific MRI contrast agent or
might also occur with other types of Gad contrast media.
In conclusion, compelling evidence challenges the safety
record of Gad contrast agents with respect to the conditions
for which they were rather indiscriminately used in the past.
We have to admit that the “carefree” days—when many of
us thought that we at last had one imaging modality
wherein contrast agents could be used nearly risk-free in
renal-failure patients—are gone.
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